share_log

Arbutus Biopharma Analyst Ratings

Arbutus Biopharma Analyst Ratings

Arbutus 生物制药分析师评级
Benzinga ·  2023/09/12 06:26
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/12/2023 172.73% HC Wainwright & Co. → $6 Reiterates Buy → Buy
08/04/2023 172.73% HC Wainwright & Co. → $6 Reiterates Buy → Buy
08/04/2023 172.73% Chardan Capital → $6 Reiterates Buy → Buy
07/11/2023 172.73% HC Wainwright & Co. → $6 Reiterates Buy → Buy
07/06/2023 172.73% JMP Securities → $6 Reiterates Market Outperform → Market Outperform
06/22/2023 172.73% HC Wainwright & Co. → $6 Reiterates Buy → Buy
06/22/2023 172.73% Chardan Capital → $6 Reiterates Buy → Buy
05/05/2023 172.73% HC Wainwright & Co. → $6 Reiterates → Buy
04/28/2023 172.73% HC Wainwright & Co. → $6 Reiterates → Buy
04/05/2023 172.73% HC Wainwright & Co. → $6 Reiterates → Buy
03/29/2023 172.73% JMP Securities → $6 Reiterates → Market Outperform
03/20/2023 172.73% HC Wainwright & Co. → $6 Reiterates → Buy
03/03/2023 172.73% Chardan Capital → $6 Reiterates → Buy
03/03/2023 172.73% HC Wainwright & Co. → $6 Maintains Buy
11/10/2022 172.73% HC Wainwright & Co. $7.5 → $6 Maintains Buy
06/28/2022 309.09% JMP Securities $10 → $9 Maintains Market Outperform
03/14/2022 286.36% HC Wainwright & Co. $8 → $8.5 Maintains Buy
03/04/2022 172.73% Chardan Capital $5.5 → $6 Maintains Buy
02/02/2022 127.27% Jefferies $4 → $5 Upgrades Hold → Buy
11/08/2021 309.09% JMP Securities $7 → $9 Maintains Market Outperform
12/17/2020 354.55% HC Wainwright & Co. → $10 Initiates Coverage On → Buy
07/24/2020 — Baird Downgrades Outperform → Neutral
05/19/2020 81.82% Wedbush $2 → $4 Upgrades Neutral → Outperform
03/27/2020 81.82% Baird $8 → $4 Maintains Outperform
03/06/2020 127.27% Chardan Capital $1.5 → $5 Upgrades Neutral → Buy
02/20/2020 263.64% Baird → $8 Initiates Coverage On → Outperform
02/05/2020 354.55% JMP Securities → $10 Upgrades Market Perform → Market Outperform
01/09/2020 172.73% B. Riley Securities $3 → $6 Maintains Buy
10/04/2019 — Chardan Capital Downgrades Buy → Neutral
10/16/2018 309.09% B. Riley Securities $11.5 → $9 Upgrades Neutral → Buy
10/15/2018 127.27% Wedbush → $5 Upgrades Underperform → Neutral
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
09/12/2023 172.73% HC Wainwright公司 →$6 重申 购买→购买
08/04/2023 172.73% HC Wainwright公司 →$6 重申 购买→购买
08/04/2023 172.73% 查尔丹资本 →$6 重申 购买→购买
07/11/2023 172.73% HC Wainwright公司 →$6 重申 购买→购买
07/06/2023 172.73% JMP证券 →$6 重申 市场表现优于→市场表现
2023/06/22 172.73% HC Wainwright公司 →$6 重申 购买→购买
2023/06/22 172.73% 查尔丹资本 →$6 重申 购买→购买
05/05/2023 172.73% HC Wainwright公司 →$6 重申 →购买
04/28/2023 172.73% HC Wainwright公司 →$6 重申 →购买
04/05/2023 172.73% HC Wainwright公司 →$6 重申 →购买
03/29/2023 172.73% JMP证券 →$6 重申 →市场跑赢大盘
03/20/2023 172.73% HC Wainwright公司 →$6 重申 →购买
03/03/2023 172.73% 查尔丹资本 →$6 重申 →购买
03/03/2023 172.73% HC Wainwright公司 →$6 维护 买
2022年11月10日 172.73% HC Wainwright公司 $7.5→$6 维护 买
2022/06/28 309.09% JMP证券 $10→$9 维护 市场表现强于大盘
03/14/2022 286.36% HC Wainwright公司 $8→$8.5 维护 买
03/04/2022 172.73% 查尔丹资本 $5.5→$6 维护 买
02/02/2022 127.27% 杰富瑞 $4→$5 升级 持有→购买
11/08/2021 309.09% JMP证券 $7→$9 维护 市场表现强于大盘
12/17/2020 354.55% HC Wainwright公司 →$10 开始承保 →购买
07/24/2020 - 贝尔德 评级下调 跑赢→中性
2020/05/19 81.82% 韦德布什 $2→$4 升级 中性→表现优异
03/27/2020 81.82% 贝尔德 $8→$4 维护 跑赢大盘
03/06/2020 127.27% 查尔丹资本 $1.5→$5 升级 中性→购买
02/20/2020 263.64% 贝尔德 →$8 开始承保 →跑赢大盘
02/05/2020 354.55% JMP证券 →$10 升级 市场表现优于→市场表现
1/09/2020 172.73% B.莱利证券 $3→$6 维护 买
2019/10/04 - 查尔丹资本 评级下调 购买→中性
2018年10月16日 309.09% B.莱利证券 $11.5→$9 升级 中性→购买
2018年10月15日 127.27% 韦德布什 →$5 升级 表现不佳的→中性

What is the target price for Arbutus Biopharma (ABUS)?

杨树的目标价是多少？

The latest price target for Arbutus Biopharma (NASDAQ: ABUS) was reported by HC Wainwright & Co. on September 12, 2023. The analyst firm set a price target for $6.00 expecting ABUS to rise to within 12 months (a possible 172.73% upside). 15 analyst firms have reported ratings in the last year.

纳斯达克(纳斯达克代码：ABUS)的最新目标价是由HC Wainwright&Co.于2023年9月12日报道的。这家分析公司将目标价定为6美元，预计abus将在12个月内上涨(可能上涨172.73%)。过去一年，有15家分析公司公布了评级。

What is the most recent analyst rating for Arbutus Biopharma (ABUS)?

Abutus Biophma(ABUS)最近的分析师评级是多少？

The latest analyst rating for Arbutus Biopharma (NASDAQ: ABUS) was provided by HC Wainwright & Co., and Arbutus Biopharma reiterated their buy rating.

纳斯达克(股票代码：ABUS)的最新分析师评级由HC Wainwright&Co.提供，Arbutus Biophma重申其买入评级。

When is the next analyst rating going to be posted or updated for Arbutus Biopharma (ABUS)?

下一次分析师评级将在什么时候发布或更新杨树(ABUS)？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arbutus Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arbutus Biopharma was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.

分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Arbutus Biophma的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Arbutus Biophma的上一次评级是在2023年9月12日提交的，所以你应该预计下一次评级将在2024年9月12日左右的某个时候公布。

Is the Analyst Rating Arbutus Biopharma (ABUS) correct?

分析师对Arbutus Biophma(ABUS)的评级正确吗？

While ratings are subjective and will change, the latest Arbutus Biopharma (ABUS) rating was a reiterated with a price target of $0.00 to $6.00. The current price Arbutus Biopharma (ABUS) is trading at is $2.20, which is within the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的Arbutus Biophma(ABUS)评级被重申，目标价在0.00美元至6.00美元之间。Arbutus Biophma(ABUS)目前的交易价格为2.20美元，在分析师的预测范围内。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发